#281

Turn Biotechnologies show Cell Reprogramming with ERA™ Technology Renews Skin

“Late-Breaking Turn Biotechnologies Presentation at ISID to Show Cell
Reprogramming with ERA™ Technology Renews Skin”

Turn Biotechnologies, a cell reprogramming company developing novel mRNA medicines for untreatable, age-related conditions, has been invited to present data showing that its epigenetic reprogramming technology rejuvenates human skin.

Turn Bio’s late-breaking abstract was accepted for presentation during the prestigious International Societies for Investigative Dermatology (ISID) Meeting, in Tokyo, Japan.

Data will show that transient reprogramming with Turn Bio’s Epigenetic Reprogramming of Aging (ERA™) technology rejuvenates cells within the extracellular matrix (ECM), resulting in comprehensive changes related to improved skin quality and structure. ERA reprogramming technology significantly reduced oxidative stress, matrix metalloproteinases (MMPs) and cellular senescence markers.

In vitro results found that ERA reprogramming increased fibroblast proliferation by more than 50% while simultaneously reversing the intrinsic hallmarks of aging.

7 Likes
#282

Profhilo is available from several sellers on Indiamart. Not sure if Ultrahilo and Profhilo give the exact same effect, but it’s an option if you wanted to try Profhilo.

2 Likes
#283

The group behind Oneskin have had a paper published in Nature. There’s some mention of Rapamycin. I’ve been using Oneskin since it launched and it’s made a huge difference. I wonder whether you could mix and match between Rapamycin and Oneskin.

Senotherapeutic peptide treatment reduces biological age and senescence burden in human skin models

Cellular senescence is known to play a role in age-related skin function deterioration which potentially influences longevity. Here, a two-step phenotypic screening was performed to identify senotherapeutic peptides, leading to the identification of Peptide (Pep) 14. Pep 14 effectively decreased human dermal fibroblast senescence burden induced by Hutchinson-Gilford Progeria Syndrome (HGPS), chronological aging, ultraviolet-B radiation (UVB), and etoposide treatment, without inducing significant toxicity. Pep 14 functions via modulation of PP2A, an understudied holoenzyme that promotes genomic stability and is involved in DNA repair and senescence pathways. At the single-cell level, Pep 14 modulates genes that prevent senescence progression by arresting the cell cycle and enhancing DNA repair, which consequently reduce the number of cells progressing to late senescence. When applied on aged ex vivo skin, Pep 14 promoted a healthy skin phenotype with structural and molecular resemblance to young ex vivo skin, decreased the expression of senescence markers, including SASP, and reduced the DNA methylation age. In summary, this work shows the safe reduction of the biological age of ex vivo human skins by a senomorphic peptide.

…

Compared to Rapamycin, Pep 14 promoted the maintenance of the overall structure of ex vivo skins of donors with different age ranges (35–79 years old) when added to culture media, leading to thicker epidermis, whereas Rapamycin treatment resulted in a more disorganized epidermal layer, and failed to increase the thickness of the epidermis (Fig. 6a, f). The mRNA expression of Pep 14-treated epidermis from ex vivo skin samples exhibited a significant decrease in the aging markers CDKN2A and B2M , the SASP marker CXCL8 , the pigmentation-related gene TYR , and a trend towards decreased SASP-related gene IL6 expression, in addition to a significant increase in KRT1 (a marker of keratinocyte terminal differentiation) and KRT14 (a marker of non-differentiated, proliferative keratinocytes) (Fig. 6b). Rapamycin induced a similar decrease in CDKN2A , CXCL8 and TYR expression, and a trend towards increased IL6 expression (Fig. 6b). In the dermis, Pep 14 treatment promoted a significant reduction in CDKN2A and B2M gene expression, as well as higher expression of the cell proliferation marker MKI67 and extracellular matrix components HYAL1 , MMP1 , COL1A1 and HAS2 . Rapamycin treatment induced CDKN2A , CXCL8 and HYAL1 reduction, and increased HAS2 (Fig. 6c). Ki-67 alterations was validated at the protein level (Fig. 6d, g). Protein levels of H2A.J were also assessed in the skins, and were reduced by both Pep 14 and Rapamycin treatment (Fig. 6e, h).

image

https://www.nature.com/articles/s41514-023-00109-1

5 Likes
#284

I’m currently using both so I hope it’s okay! They seem to work well together.

4 Likes
#285

This is the same concentration of Rapamycin that OneSkin used in their past paper, which is extremely low at 100 nM. The amount they used would be about 0.005 mg dissolved in 56 mL of lotion. The Drexel study on the other hand was 10 uM Rapamycin, or about 0.5 mg dissolved in the same amount of lotion. The least they could have done would be to use the same concentration used in the Drexel study. I find it very misleading.

oneskin
oneskin907×167 67 KB

9 Likes
#286

@blsm do you use topical rapamycin too?

1 Like
#287

@scta123, yes. I made a spray inspired by Desertshores.

1 Like
#288

@blsm that is cool! Do report back! Using transcutol? I wanted to make it, but it seemed too complex to get ingredients and there was so much different concentrations used in different studies and in experiments here that I gave up… but I keep it the back of my mind.

2 Likes
#289

Apologies for my ignorance but I understood that Drexel study was 0.003%? So I had prepared a cream of 0,004 % by local pharmacy : did I ask wrong ?

On the packaging of 100 ml is written : 0,004 g sirolimus ( 50 euros , i used in morning and evening and no issues ; but did I ask too little ?)

Thanks so much for your kind help and clarification :pray:

#290

The Drexel study was about 0.001% solution, so 0.004% is very close. People here on the forum are making and using various stronger doses of 0.011% (Methusela), 0.045% (Dr. Green’s amount supposedly), and up to 0.1 or 0.2% (Agetron, through a pharmacy I believe). Stronger formulations haven’t been tested, so we don’t know if stronger is better.

6 Likes
#291

Where do you live @eli? I tried to get cream done in my local pharmacy, but they said they could not prepare it since they do not have trascutol… Is yours prepared with trascutol? I was thinking maybe I get it when I travel somewhere as buying transcutol and grinding the pills myself is not the most enjoyable thought :sweat_smile: but at the end maybe I will.

1 Like
#292

Living in Spain but I just bought it in Italy ( Rome ) too without issues ; trascutol is not specified on the packaging; it merely mentions : “ eudermic crème basis “

image
image729×1904 269 KB

(And a tiny bit of sweet almond oil)

I also wanted to see effect ( and know costs ) before possibly making my own and investing in tools

One skin unfortunately does not seem to be available in EU

2 Likes
#293

Pardon my ignorance…does the product “Oneskin” contain the senolytic peptide or is it something different again? I have downloaded and read the peptide paper and it looks very interesting.
I need something…my face is starting to resemble that of a rather hastily-embalmed lizard!

1 Like
#294

Skin aging is a multifaceted process that involves intrinsic and extrinsic mechanisms that lead to various structural and physiological changes in the skin. Intrinsic aging is associated with programmed aging and cellular senescence, which are caused by endogenous oxidative stress and cellular damage. Extrinsic aging is the result of environmental factors, such as ultraviolet (UV) radiation and pollution, and leads to the production of reactive oxygen species, ultimately causing DNA damage and cellular dysfunction. In aged skin, senescent cells accumulate and contribute to the degradation of the extracellular matrix, which further contributes to the aging process. To combat the symptoms of aging, various topical agents and clinical procedures such as chemical peels, injectables, and energy-based devices have been developed. These procedures address different symptoms of aging, but to devise an effective anti-aging treatment protocol, it is essential to thoroughly understand the mechanisms of skin aging. This review provides an overview of the mechanisms of skin aging and their significance in the development of anti-aging treatments.

Open Access Paper:

#295

Thx. @eli. This is the same as I can get here in my local pharmacy. It is standard European compounding ingredient. Maybe I will have to invest into some transcutol and do it myself… or see if any european studies were not using transcutol and still got results…

This are the ingredients:
purified water, white petrolatum, cetyl and stearyl alcohol, liquid paraffin, macrogol cetyl stearyl ether, benzyl alcohol, sodium dihydrogen phosphate monohydrate, phosphoric acid, sodium hydroxide

1 Like
#296

Yes it contains the peptide. I’ve found it to be very effective. I noticed the most difference in the first couple of months. My skin became visibly tighter and smoother. Quite a stark change actually. The downside is that it’s quite expensive. It’s become quite the hit within my circles.

9 Likes
#297

OneSkin really helped the crepey skin on my legs that I’ve had ever since losing a lot of weight.

6 Likes
#298

Hey thanks for your reply Paul!

I’ll see if I can track some down.

1 Like
#299

So is transcutol better then ?
Any idea on EU alternative for Oneskin?
Thanks :blush:

#300

It’s only currently available in the US I believe.